ArticleACS measurement science au2026
Structural Lipidomics Uncovers CC Location-Specific Lipid Signatures and the Response to Immune Checkpoint Inhibitor in dMMR/MSI‑H Colorectal Cancer.
Article in ACS measurement science au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Lipid Metabolic Reprogramming to Overcome Immunotherapy Resistance: Systemic Nutritional Modulation and Precision Nanomedicine.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipidomics offers valuable insights for cancer research. Paternò-Büchi (PB) reaction-based LC-MS/MS enables precise lipid structural resolution at the CC location level. Although mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) status predicts anti-PD-1 response in colorectal cancer (CRC), nearly half of the patients do not benefit, underscoring the need for better biomarkers. Here, we applied sequential LC-MS, LC-MS/MS, and LC-PB-MS/MS to profile serum lipids from 58 dMMR/MSI-H CRC patients receiving anti-PD-1 treatment. The resulting lipidomic data were subsequently explored to identify predictive biomarkers for efficacy. We identified 814 glycerophospholipids, 285 of which were resolved at the CC location level. Comparative analyses revealed 56 differential lipids between patients achieving complete response (CR) and progressive disease (PD) before treatment and 214 after therapy (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.